Onchilles Pharma is at the forefront of cancer treatment innovation, focusing on the ELANE pathway, a novel innate immune mechanism discovered by Dr. Lev Becker. This pathway utilizes catalytically active neutrophil elastase (ELANE) to selectively target and kill cancer cells while preserving healthy tissue. The company is developing a range of biologic drug candidates, including NEU-001 and NEU-002, which are designed for intratumoral and intravenous delivery, respectively. These candidates have demonstrated significant efficacy in preclinical models, inducing immunogenic cell death across various tumor types, including head & neck, skin, breast, and lung cancers. Onchilles Pharma aims to initiate first-in-human clinical trials in 2025, marking a pivotal step in validating the therapeutic potential of the ELANE pathway.

The ELANE pathway's unique mechanism allows for the eradication of cancer cells irrespective of their genetic makeup or anatomical origin, positioning Onchilles Pharma's therapies as potential first-in-class treatments. NEU-002, in particular, has shown promise in overcoming challenges associated with systemic delivery, enhancing substrate specificity, and selectively inducing cancer cell death in primary human tissues. The preclinical data suggest that these therapies could not only provide immediate tumor responses but also foster immune memory, potentially leading to durable clinical benefits. As Onchilles Pharma advances its pipeline, the focus remains on leveraging the ELANE pathway to redefine cancer treatment standards and improve patient outcomes.

United States

Onchilles Pharma was founded on breakthrough research of a novel neutrophil pathway that when activated selectively and comprehensively kills cancer cells. Based on this research, the private biotech company is developing a pipeline of first-in-class drug candidates that have the potential to be broadly effective against a wide range of cancers. Onchilles is headquartered at the Alexandria GradLabs in San Diego.

Onchilles Pharma

Company Details